.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 7,101,960

« Back to Dashboard

Claims for Patent: 7,101,960

Title:Process for removing bile salts from a patient and alkylated compositions therefor
Abstract:The invention relates to a method for reducing serum cholesterol in a patient in need thereof and alkylated and crosslinked poly(allylamine) polymers useful in the method. The alkylated and crosslinked poly(allylamine) polymers are crosslinked with epichlorohydrin and comprise at least some n-decyl substituted nitrogen atoms and at least some hexyltrimethyl ammonium substituted nitrogen atoms.
Inventor(s): Mandeville, III; W. Harry (Lynnfield, MA), Holmes-Farley; Stephen Randall (Arlington, MA)
Assignee: Genzyme Corporation (Cambridge, MA)
Application Number:10/886,016
Patent Claims: 1. An alkylated and crossliniced poly(allylamine)polymer salt, comprising: (a) at least some n-decyl substituted nitrogen attoms; and (b) at least some hexyltrimethylammonium substitutcd nitrogen atoms, wherein the hexyltrimethylammonium has the structural formula --CH.sub.2(CH.sub.2).sub.5N.sup.-(CH.sub.3).sub.3 and wherein the alkylated and crosslinked poly(allylamine)polymer salt is crosslinked with epichlorohydrin.

2. The alkylated and crosslinked poly(allylamine)polymer salt of claim 1, having halide counterions.

3. The alkylated and crosslinked poly(allylamine)polymer salt of claim 2, having countetons selected from the group consisting of Cl.sup.-; Br.sup.-, and mixtures. thereof.

4. The alkylated and crosslinked poly(allylamine)polymer salt of claim 3, wherein the epichlorohydrin crosslinks between about 0.5 and 20% of the amine groups of the alkylated and crosslinked poly(allylamine)polymer salt.

5. The alkylated and crosslinked poly(allylamine)polymer salt of claim 4, having halide counterions.

6. The alkylated and crosslinked poly(allylamine)polymer salt of claim 5, having counterions selected from the group consisting of Cl.sup.-, Br.sup.-, and mixtures thereof.

7. A pharmaceutical composition comprising: (a) a pharmaceutically acceptable carrier, and (b) an alkylated and crosslinked poly(allylamine)polymer salt including: (i) at least some n-decyl substituted nitrogen atoms; and (ii) at least some hexyltrimethylammonium substituted nitrogen atoms, wherein the hexyltrimethylammonium has the structural formula --CH.sub.2(CH.sub.2).sub.5N.sup.-(CH.sub.3).sub.3 and wherein the alkylated and crosslinked poly(allylamine)polymer salt is crosslinked with epichlorohydrin.

8. The pharmaceutical composition of claim 7, wherein the alkylated and crosslinked poly(allylamine)polymer salt has halide counterions.

9. The pharmaceutical composition of claim 8, wherein the alkylated and crosslinked poly(allylamine)polymer salt has counterions selected from the group consisting of Cl.sup.-, Br.sup.-, and mixtures thereof.

10. The pharmaceutical composition of claim 7, wherein the epichlorohydrin crosslinks between about 0.5 and 20% at the amine groups of the alkylated and crosslinked poly(allylamine)polymer salt.

11. The pharmaceutical composition of claim 10, wherein the alkylated and crosslinKed poly(allylamine)polymer salt has halide counterions.

12. The pharmaceutical composition of claim 11, wherein the alkylated and crosslinked poly(allylamine)polymer salt has counterions selected from the group consisting of Cl.sup.-, Br.sup.-, and mixtures thereof.

13. A method of reducing the serum cholesterol of a patient, comprising orally administering to said patient a therapeutically effective amount of an alkylated and crosslinked poly(allylamine)polymer salt, comprising; (a) at least some n-decyl substituted nitrogen atoms; and (b) at least some hexyltrimethylammonium substituted nitrogen atoms, wherein the hexyltrimethylammonium has the structural formula --CH.sub.2(CH.sub.2).sub.5N.sup.-(CH.sub.3).sub.3 and wherein the alkylated and crosslinked poly(allylamine)polymer salt is crosslinked with epichlorohydrin.

14. The method of claim 13, wherein the alkylated and crosslinked poly(allylamine)polymer has halide counterions.

15. The method of claim 14, wherein the alkylated and crosslinked poly(allylamine)polymer has counterions selected from the group consisting of Cl.sup.-; Br.sup.-, and mixtures thereof.

16. The method of claim 13, wherein the epichlorohydrin crosslinks between about 0.5 and 2% of the amine groups of the alkylated and crosslinked poly(allylamine)polymer salt.

17. The method of claim 6, wherein the alkylated and crosslinked poly(allylamine)polymer has halide counterions.

18. The method of claim 17, wherein the alkylated and crosslinked poly(allylamine)polymer has counterions selected from the group consisting of Cl.sup.-, Br.sup.-, and mixtures thereof.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc